Document is current
Any future updates will be listed below
-
Authors
Moradi, Mehri https://orcid.org/0000-0001-9550-8701
Weingart, Julia https://orcid.org/0000-0001-9302-6047
Deng, Chunchu https://orcid.org/0000-0002-5533-6009
Nasouti, Mahoor
Briese, Michael https://orcid.org/0000-0001-7137-8260
Jablonka, Sibylle https://orcid.org/0000-0002-4517-3760
Sauer, Markus https://orcid.org/0000-0002-1692-3219
Sendtner, Michael https://orcid.org/0000-0002-4737-2974
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SA 829/17-1, SA829/19-1, SE 697/7-1)
- License Information
-
More Information
Article History
Received: 22 October 2024
Accepted: 8 September 2025
First Online: 30 September 2025
Competing interests
: M. M. and M. Sendtner are inventors on two patents that have been applied for by the Julius-Maximilians-Universität Würzburg and were recently published as WO 2025026896A1 and WO 2025026772A1. The patent application with the number WO 2025026772A1 was designed to protect the use of the Munc13-1 hybrid molecule described in this manuscript for the treatment of Spinal Muscular Atrophy and other motoneuron disorders. The patent application with the number WO 2025026896A1 refers to the local presynaptic modulation of Munc13-1 expression for the treatment of motoneuron disorders. The remaining authors declare no competing interests.
